CenTrial Logo

Nebulizer Provides Relief for Fluid Buildup in the Middle Ear


Clinical trial that manosonic nebulizer is effective for treating fluid buildup in the middle ear

Otitis media with effusion (OME) is a condition where fluid builds up in the middle ear, usually without any signs of infection or inflammation. It is sometimes called "glue ear" because the fluid may become thick and sticky. OME can be caused by various factors, including allergies, changes in air pressure (such as during air travel), and inflammation of the Eustachian tube, which connects the middle ear to the back of the nose and throat.

The symptoms of OME can include mild to moderate hearing loss, a feeling of pressure or fullness in the ear, and sometimes mild pain or discomfort. However, many people with OME have no symptoms at all. Treatment for OME may include watchful waiting, antibiotics (if there is an underlying infection), or surgical intervention to drain the fluid or insert a ventilation tube (also known as a "grommet" or "tympanostomy tube") to help equalize pressure and prevent future fluid buildup.

Aerosol drug administration is the primary treatment for OME, and the automatic manosonic aerosol generator (AMSA) (manosonic nebulizer) is a device that delivers therapeutic doses of drugs to the middle ear by inhalation of an aerosol. However, there is limited research on the efficacy of AMSA treatment, particularly in adults. This pilot single-arm clinical trial aimed to assess the changes in adults with OME following treatment with AMSA.

Are you interested in clinical trials near you?

You can receive free notification of a trial for this, or any other condition, by completing a short confidential health profile.
Find a clinical trial near me
The study included 36 patients with OME who received a three-day treatment with inhaled mucolytic and steroids administered by AMSA. Tympanometry was performed to measure middle ear effusion before and after the intervention. Tympanometry is a test that measures the eardrum's movement in response to changes in air pressure. The results showed that partial and complete OME remission was observed in 81% and 39% of patients, respectively. Following the intervention, an increase in middle ear volume and pressure and a higher proportion of patients achieving categorical normalization of compliance and pressure were observed.

The study found that treatment efficacy was not affected by age, sex, or recruitment season. However, the use of AMSA management of OME in adults must be verified in future studies. While the results of this pilot study are encouraging, further research is required to validate the efficacy of AMSA treatment in a larger sample size and randomized controlled trials.


This study provides preliminary evidence that AMSA treatment may effectively manage OME in adults. The device can deliver therapeutic doses of drugs directly to the middle ear, resulting in partial or complete remission of OME. While the findings are promising, further research is required to confirm the efficacy of AMSA treatment and establish its role in managing OME in adults.

Share this article with a friend:

Get emailed clinical trial results in the categories of your choice:
Free subscription to clinical trial results

20,000 clinical trials are seeking participants.
Signup and be matched to trials near you
This free service will notify you of current and future clinical trial matches.

This content is for informational and educational purposes only. It is not intended to provide medical advice or to take the place of such advice or treatment from a personal physician. All readers/viewers of this content are advised to consult their doctors or qualified health professionals regarding specific health questions. CenTrial Data Ltd. does not take responsibility for possible health consequences of any person or persons reading or following the information in this educational content. Treatments and clinical trials mentioned may not be appropriate or available for all trial participants. Outcomes from treatments and clinical trials may vary from person to person. Consult with your doctor as to whether a clinical trial is a suitable option for your condition. Assistance from generative AI tools may have been used in writing this article.